Stock MAAT MAAT PHARMA
Add to a list
To use this feature you must be a member
Log inSign up

All News MaaT Pharma

Equities

MAAT

FR0012634822

Market Closed - Euronext Paris
Other stock markets
 11:20:58 2024-06-28 EDT 		5-day change 1st Jan Change
7.16 EUR -4.79% Intraday chart for MaaT Pharma +3.77% +2.58%
06-24 MaaT Pharma SA Pharma Appoints Gianfranco Pittari, M.D. Ph.D, as Chief Medical Officer CI
05-08 Mickey Mouse on Wall Street Our Logo

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
MaaT Pharma Announces Initiation of Coverage of its Stock by Stifel with a Buy Rating and a Target Price of EUR 16
BU
MaaT Pharma Appoints Gianfranco Pittari, M.D. Ph.D, as Chief Medical Officer
BU
MaaT Pharma SA Pharma Appoints Gianfranco Pittari, M.D. Ph.D, as Chief Medical Officer
CI
MaaT Pharma Presents the Results of its Annual Ordinary and Extraordinary General Meeting
BU
May 15, 2024: MaaT Pharma announces the successful completion of its Global Offering of 19.2 Million Euros
PU
MaaT Pharma announces the successful completion of its Global Offering of 19.2 Million Euros
BU
MaaT Pharma : Inside Information / News release on accounts, results
PU
MaaT Pharma Launches a Global Offering of approximately 18 Million Euros
BU
May 14, 2024: MaaT Pharma Launches a Global Offering of approximately 18 Million Euros
PU
Mickey Mouse on Wall Street
Our Logo
MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2024
BU
MaaT Pharma to Hold Annual General Meeting on May 28, 2024
BU
Long-term data indicates "significant" potential of aGvHD microbiome treatment
AQ
MaaT Pharma: positive data in graft-versus-host disease
CF
MaaT Pharma Presents Positive 18-month Data for MaaT013 Showing a Clear Overall Survival Advantage in aGvHD from the Early Access Program at the 2024 EBMT Event
BU
MaaT Pharma Presents Positive 18-Month Data for MaaT013 Showing a Clear Overall Survival Advantage in aGvHD from the Early Access Program at the 2024 EBMT Event
CI
Advancing microbiome innovation
AQ
MaaT Pharma Presents Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to Immunotherapies
BU
MaaT Pharma Presents Promising Preclinical Data at AACR for MaaT034 Aiming to Improve Patients? Responses to Immunotherapies
CI
MaaT Pharma Announces Initiation of Coverage of its Stock by Gilbert Dupont, Groupe Societe Generale
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MAAT Stock
  4. News MaaT Pharma